Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk - Wikidata - wikimedia - TriplyDB

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

http://www.wikidata.org/entity/Q28244692

about

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma Early events during neoplastic progression in Barrett's esophagus Predictive biomarkers for Barrett's esophagus: so near and yet so far Alterations of the TP53 gene in gastric and esophageal carcinogenesis Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction Screening for Barrett's Esophagus Barrett's oesophagus: frequency and prediction of dysplasia and cancer Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.Clinical puzzle: Barrett's oesophagus.Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach.A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma Low grade dysplasia in Barrett's esophagus: Should we worry?Evidence for DNA damage checkpoint activation in barrett esophagus MicroRNA-196a & microRNA-101 expression in Barrett's oesophagus in patients with medically and surgically treated gastro-oesophageal reflux.Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.A 115-bp MethyLight assay for detection of p16 (CDKN2A) methylation as a diagnostic biomarker in human tissues.Barrett's esophagus and cancer risk: how research advances can impact clinical practice.Biomarkers in Barrett's Esophagus.Barrett's esophagus: progression to adenocarcinoma and markers.Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction.Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.Biomarkers of Barrett's esophagus.Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.Genome-wide epigenetic modifications in cancer.The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.American Gastroenterological Association technical review on the management of Barrett's esophagus

P2860

Q21563424-912601B4-9A21-44B6-8740-2F3F92A4D5E5 Q24297348-83D4BBE8-C56E-4B86-9C0F-0A2C0E2D148F Q24632246-B4FBBCF2-CCBF-4386-A435-843EA947922F Q26825349-9103815E-7FE3-4DF5-92C9-D9FF90E01D58 Q26849403-078DFFAE-032C-4F78-A710-4E275773400C Q26866191-98C2473C-B580-45E2-8BD2-C8925C7B7818 Q27026253-34B6CE6A-DA13-460C-9CBE-7FAEE685B04F Q28080445-88389EC9-3C02-42F0-AB1F-AD5D75174458 Q28080794-E5B1A1AB-C6EF-46F1-BD88-FBE1A2CBCA07 Q30412980-D65C9CF1-C518-4CBE-9592-C61E8B3EE4C9 Q30436675-8C443D30-5F6A-4C47-9B76-E51B76B1010C Q30445130-1F08E715-4BD6-4ADF-8243-48FB73314358 Q33253913-3B8AFD8E-C867-44FF-A008-053A6AA4AD21 Q33326627-354F6DB5-5224-4F2A-9F59-B3363DF8B08C Q33346381-55451C4B-797D-4ACE-81F1-0A1AF05809D9 Q33429064-1F34E5DF-E255-4C79-9564-205C7784C77B Q33529283-9D0B8BA2-AFB4-4817-898E-351EBA377A45 Q33628118-546F5EB0-C5B3-4DAB-83ED-756D4FAB4EB9 Q33655360-164BE0F5-EA3D-47FA-BD30-4EE57F4D0A23 Q33830204-9BA4209F-8562-4E92-9461-AD29C94974CB Q33869648-4A22E3E1-30A9-4DC4-ADC9-FD3379444C07 Q33899068-280D0D13-5902-4801-8B78-61A8D1EADC09 Q33959620-49E8C91A-F115-4826-9B1D-14CB0817196A Q34011000-5C39E195-074B-45E1-93F9-ED76983AECCF Q34032319-BA726C82-ABA5-44E3-84AE-17CC2D7C91CF Q34050233-53578E6A-5731-40A3-8D92-D205A6C3713B Q34088277-29674C09-56D6-418D-829A-8F85154104F9 Q34193813-E70F0EFC-AE97-4419-8C81-5DEF4C5EAA24 Q34385125-149900CA-3935-43A6-B5B9-E944F3F0188A Q34448115-813A640E-5144-47AE-BDB4-5869A81E55CB Q34621907-632C4C88-C781-427E-AB8B-4538DC397969 Q34731480-1103C918-6F0B-4290-B338-5F1C8F5C3EEF Q34818554-4C17B982-4773-4FFD-A26B-A38A51110A63 Q34958192-FF627AED-B121-4B2D-A34F-0B518B7042AC Q34979616-45B872A9-596D-445D-BCF4-C5B62FE9EC9B Q35031044-54556C2D-EA9C-4883-A2A4-7F9608E7D4A7 Q35257951-C59BBEB4-F0D1-4A14-A57B-0374D6D4EA17 Q35399306-8B89BD92-D8D0-49BA-8F69-7413A0A07B12 Q35666515-E486E89D-B19C-4787-9B5B-C17C3F3A48CE Q35673305-DEF6B030-1C0E-4061-BC86-5C602E3FED7E

P2860

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

http://www.wikidata.org/entity/Q28244692

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@ast

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@en

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@nl

type

label

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@ast

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@en

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@nl

prefLabel

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@ast

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@en

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@nl

P1433

Q28244692-D9861E8D-B69F-4ADB-AF7C-23FBFCDD5D5C

P1476

Q28244692-438A6814-EC3A-4A06-9966-F8B7A6104E81

P2093

Q28244692-02E86D89-7F36-4870-9114-B3C4A564CEE7

Q28244692-0D5AA230-A063-4D97-8DA5-BF42FC9B606D

Q28244692-121CE84D-880E-47AE-986E-5F4DD13FBDFA

Q28244692-2C1E580B-33A0-4D10-AB0C-A621D47B439A

Q28244692-46ECD33A-856D-4DC1-B595-ED0F1789CCE8

Q28244692-48EB1915-1724-4C66-8DE1-5F837C8EB4E0

Q28244692-4FD63617-19CE-4893-9C5B-784B4D1DD7BE

Q28244692-60AC573F-92F9-40D2-984A-6D80052CADA2

Q28244692-809D423C-00DC-4374-A02F-7FE0E060391B

Q28244692-8A017A47-DDD1-4433-B32D-FA9195D1D8A8

P2860

Q28244692-096046C6-2C99-4B62-AB89-297D41BCCD0E

Q28244692-0F24D5F0-A16F-49B7-ACDC-1B2DFB5EC2FD

Q28244692-21828110-52FD-45F5-A2EA-D30AE42EAACE

Q28244692-2DAE84E9-5662-4725-892C-F1F7877ABC0B

Q28244692-34B62F8F-608A-4D58-87B5-FABAFEFC37DA

Q28244692-47475C23-44E1-4A71-BDB2-22F886DD085F

Q28244692-7B0D97A3-6677-4E63-AB36-DFC17BE8779D

Q28244692-829BD853-7EB1-4B25-8A67-610F83AF7682

Q28244692-8BB57DDF-3E26-4046-8F31-187AC670411C

Q28244692-8C8436B9-4094-452E-BB09-6BF48B2062BD

P2888

Q28244692-BD767E96-6492-4D02-BF47-08D19B1B1D4C

P304

Q28244692-ABCEE185-0B87-4D8C-AB57-5B7A399843F4

P31

Q28244692-59A5DECD-E8BA-4B0D-8765-41A1900F0FB0

P356

Q28244692-A1EA18AB-B7BE-4C11-86C8-B86B4347516E

P407

Q28244692-EB9F53C5-0662-4F9D-B84D-DD0D0F47123C

P433

Q28244692-E38DD706-B8CA-48EE-8D35-B59FF24E3B40

P478

Q28244692-6FC7149C-26A9-4E11-A00C-BA39C1A69B7E

P50

Q28244692-160AB0E0-5C4B-44EF-B3C1-EAC605E8B314

P577

Q28244692-7662F710-24CA-4A32-890D-34B72547D662

P5875

Q28244692-EB490668-F6A1-4842-9123-2B076153724B

P6179

Q28244692-A0DD69F3-A2A9-4B7D-8D26-CE268F2F8678

P698

Q28244692-1AF32A05-0373-4D6D-8CA3-70555DC6C937

P356

P1433

P1476

Inactivation of p16, RUNX3, an ...... and predicts progression risk

@en

P2093

Anca Sterian

http://www.w3.org/2001/XMLSchema#string

Andreea Olaru

http://www.w3.org/2001/XMLSchema#string

Bruce D Greenwald

http://www.w3.org/2001/XMLSchema#string

David G Beer

http://www.w3.org/2001/XMLSchema#string

Elena Deacu

http://www.w3.org/2001/XMLSchema#string

Fumiaki Sato

http://www.w3.org/2001/XMLSchema#string

James Hamilton

http://www.w3.org/2001/XMLSchema#string

Jing Yin

http://www.w3.org/2001/XMLSchema#string

John M Abraham

http://www.w3.org/2001/XMLSchema#string

Karsten Schulmann

http://www.w3.org/2001/XMLSchema#string

P2860

Evolution of neoplastic cell lineages in Barrett oesophagus

Nonparametric Estimation from Incomplete Observations

Biallelic inactivation of the RIZ1 gene in human gastric cancer

Causal relationship between the loss of RUNX3 expression and gastric cancer

Gene silencing in cancer in association with promoter hypermethylation

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue

Chemoprevention for Barrett's esophagus trial. Design and outcome measures.

Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.

Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

P2888

P304

4138-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1208598

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7911688

http://www.w3.org/2001/XMLSchema#string

P6179

1038478569

http://www.w3.org/2001/XMLSchema#string

P698

15824739

http://www.w3.org/2001/XMLSchema#string